Clinical Effectiveness of Canagliflozin 100mg in T2DM Patients-A Real-World Study

被引：1
|
作者：
Chakravorty, Saibal, Sr.
Patel, Vikas Kumar
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2359-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2359-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Switching to Insulin Degludec Improves Glycemic Control in Patients with T2DM in a Real-World Setting
    Schultes, Bernd
    Tentolouris, Nikolaos
    Knudsen, Soren T.
    Lapolla, Annunziata
    Eidenmueller, Markus
    Prager, Rudolf
    Phan, Tra-Mi
    Wolden, Michael L.
    Siegmund, Thorsten
    DIABETES, 2017, 66 : A266 - A266
  • [22] Canagliflozin review - safety and efficacy profile in patients with T2DM
    Jakher, Haroon
    Chang, Tara I.
    Tan, Marilyn
    Mahaffey, Kenneth W.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 209 - 215
  • [23] Real-World Treatment for Diabetic Nephropathy (DN) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Chaudhari, Paresh
    Zhou, Zhou
    Yang, Hongbo
    Zhao, Jing
    Wu, Eric
    Seifeldin, Raafat
    DIABETES, 2016, 65 : A603 - A603
  • [24] REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS INITIATING INJECTABLE TREATMENTS FOR TYPE 2 DIABETES MELLITUS (T2DM): PILOT DATA FROM THE INITIATOR STUDY
    Grabner, M.
    Wei, W.
    Raparla, S.
    Quimbo, R. A.
    Cziraky, M. J.
    Thayer, S. W.
    Brekke, L.
    Buysman, E.
    Crown, W.
    Hu, W.
    Cuddihy, R.
    VALUE IN HEALTH, 2012, 15 (07) : A494 - A494
  • [25] Therapeutically Exchangeable? A Real-World Outcome Study of Switching between Basal Insulin Analogs among T2DM Patients
    Levin, Philip
    Wei, Wenhui
    Miao, Raymond
    Xie, Lin
    Ye, Fen
    Baser, Onur
    Gill, Jasvinder K.
    DIABETES, 2014, 63 : A234 - A234
  • [26] Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)
    Singhal, Mukul
    Tan, Hiangkiat
    Coleman, Craig I.
    Herman, William H.
    Cai, Jennifer
    Han, Michelle
    Ingham, Mike
    DIABETES, 2018, 67
  • [27] Real-World Impact of Canagliflozin on Glycemic Control, Body Weight, and Blood Pressure in Whites and African Americans with Type 2 Diabetes Mellitus (T2DM)
    Lefebvre, Patrick
    Chow, Wing
    Pilon, Dominic
    Emond, Bruno
    Lafeuille, Marie-Helene
    Pfeifer, Michael
    Rupnow, Marcia F. T.
    Duh, Mei Sheng
    DIABETES, 2016, 65 : A306 - A306
  • [28] A real-world retrospective evaluation of glycaemic control and weight loss in patients with type 2 diabetes mellitus treated with canagliflozin 100 mg and canagliflozin 300 mg in an Indian setting
    Mukherjee, Poulomi
    Roychoudhury, Soumyabrata
    Majumder, Anirban
    CLINICAL DIABETOLOGY, 2020, 9 (05): : 300 - 305
  • [29] Efficacy of canagliflozin (CANA) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in patients with T2DM: Results from RCTs and Real-World (RW) study
    Canovatchel, William
    Thayer, Sarah
    Chow, Wing
    Qiu, Rong
    Davies, Michael
    Fegade, Mayuresh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S118 - S118
  • [30] Real-World Evidence that Impaired Awareness of Hypoglycemia Increases Severe Hypoglycemia Rates in T2DM (InHypo-DM Study)
    Ratzki-Leewing, Alexandria
    Harris, Stewart B.
    Au, Natalie H.
    Webster-Bogaert, Susan
    Brown, Judith B.
    Reichert, Sonja M.
    Ryan, Bridget L.
    DIABETES, 2019, 68
12345